Showing 81 - 94 results of 94 for search '"drug safety"', query time: 0.11s Refine Results
  1. 81

    Pregnant Women, a Potential Reservoir for Onchocerca volvulus? A Cross Sectional Study in Maridi County, South Sudan by Chiara Trevisan, Amber Hadermann, Stephen Raimon Jada, Raphael A. Abong, Yak Yak Bol, Joseph N. Siewe Fodjo, Katja Polman, Robert Colebunders

    Published 2025-02-01
    “…Pregnant women may be a parasite reservoir as they are not included in routine ivermectin (IVM) treatments due to unassessed drug safety. In our study we determined the proportion of pregnant women infected with Onchocerca volvulus and assessed the knowledge and practices on IVM use during pregnancy. …”
    Get full text
    Article
  2. 82

    High risk for life-threatening adverse events of fluoroquinolones in young adults: a large German population-based cohort study by Julia Wicherski, Jonas Peltner, Cornelia Becker, Katrin Schüssel, Gabriela Brückner, Andreas Schlotmann, Helmut Schröder, Winfried V. Kern, Britta Haenisch

    Published 2025-02-01
    “…Conclusions This study contributes real-world evidence to endpoint-specific differences of risks in patient subgroups which need to be considered to improve fluoroquinolone drug safety.…”
    Get full text
    Article
  3. 83
  4. 84
  5. 85

    Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-... by Caroline J. Stone, Geeta Ahuja, Lais Lopes Almeida Gomes, Joy Poroye, Daniella Forman Faden, Lillian Xie, Rui Feng, Barbara White, Victoria P. Werth

    Published 2025-01-01
    “…The OLE consisted of a 3-year period during which 20 patients were on the drug for the entire duration, with assessments every 8 weeks to evaluate drug safety and efficacy. Subsequently, a follow-up retrospective chart review was performed on patients who completed the OLE as well as on control subjects with DM who did not participate in the lenabasum trial. …”
    Get full text
    Article
  6. 86

    A Pharmacokinetic/Pharmacodynamic Study of Esomeprazole Comparing a Dual Delayed-Release Formulation (YYD601) to a Conventional Formulation Following Multiple Administrations in He... by Lee HW, Kang WY, Park JS, Lee JH, Park JJ, Gwon MR, Yoon YR, Seong SJ

    Published 2025-01-01
    “…Hae Won Lee,1 Woo Youl Kang,2 Ji Seo Park,1 Jae Hwa Lee,1 Jin Ju Park,1 Mi-Ri Gwon,1 Young-Ran Yoon,1 Sook Jin Seong1 1School of Medicine, Kyungpook National University and Department of Clinical Pharmacology and Therapeutics, Kyungpook National University Hospital, Daegu, 41944, Republic of Korea; 2Clinical Trial Dossier Evaluation Team, Innovative Products Support Department, National Institute of Food and Drug Safety Evaluation, Cheongju, 28159, Republic of KoreaCorrespondence: Young-Ran Yoon, Professor, School of Medicine, Kyungpook National University and Department of Clinical Pharmacology and Therapeutics, Kyungpook National University Hospital, 130 Dongdeok-Ro, Jung-gu, Daegu, 41944, Republic of Korea, Tel +82-53-420-4950, +82-53-420-5218, Email yry@knu.ac.kr Sook Jin Seong, Clinical Associate Professor, School of Medicine, Kyungpook National University and Department of Clinical Pharmacology and Therapeutics, Kyungpook National University Hospital, 130 Dongduk-Ro, Jung-gu, Daegu, 41944, Republic of Korea, Tel +82-53-200-6351, +82-53-420-5218, Email wintersj@knu.ac.krBackground: YYD601 is a new dual delayed-release formulation of esomeprazole, developed to enhance plasma exposure and prolong the duration of acid suppression.Purpose: This study aimed to evaluate the safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of YYD601 20 mg following single and multiple oral administrations in healthy, fasting adult Koreans, and to compare these outcomes to those of the conventional esomeprazole 20 mg capsule.Methods: A randomized, open-label, two-period crossover study was conducted in 28 participants, who were divided into two treatment groups: one group received YYD601 20 mg, and the other received conventional esomeprazole 20 mg, once daily for five consecutive days. …”
    Get full text
    Article
  7. 87
  8. 88
  9. 89

    Discovery of Novel Nav1.7-Selective Inhibitors with the 1H-Indole-3-Propionamide Scaffold for Effective Pain Relief by Gaoang Wang, Hang Wu, Yingying Wang, Xiangying Liu, Shuijiao Peng, Wenxing Wang, Meijing Wu, Yifei Liu, Ercheng Wang, Zhe Wang, Lei Xu, Xiaojian Wang, Wei Yang, Haiyi Chen, Xi Zhou, Tingjun Hou

    Published 2025-01-01
    “…Additionally, it displays favorable subtype selectivity and positive drug safety in acute toxicity studies. Pharmacokinetic studies indicate that WN2-R has high bioavailability (F = 20.29%), highlighting its considerable potential for drug development. …”
    Get full text
    Article
  10. 90
  11. 91
  12. 92
  13. 93
  14. 94